Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Davita Healthcare Partners Inc (DVA)

Davita Healthcare Partners Inc (DVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,147,060
  • Shares Outstanding, K 82,000
  • Annual Sales, $ 12,140 M
  • Annual Income, $ 691,540 K
  • EBIT $ 2,686 M
  • EBITDA $ 3,432 M
  • 60-Month Beta 0.89
  • Price/Sales 1.04
  • Price/Cash Flow 9.18
  • Price/Book 21.58

Options Overview Details

View History
  • Implied Volatility 29.22% ( -1.71%)
  • Historical Volatility 43.11%
  • IV Percentile 31%
  • IV Rank 16.88%
  • IV High 51.18% on 08/05/24
  • IV Low 24.76% on 08/30/24
  • Put/Call Vol Ratio 0.15
  • Today's Volume 305
  • Volume Avg (30-Day) 1,315
  • Put/Call OI Ratio 2.90
  • Today's Open Interest 55,858
  • Open Int (30-Day) 50,877

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 2.21
  • Number of Estimates 2
  • High Estimate 2.31
  • Low Estimate 2.11
  • Prior Year 1.87
  • Growth Rate Est. (year over year) +18.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
138.00 +16.18%
on 10/30/24
168.50 -4.85%
on 10/16/24
-4.24 (-2.58%)
since 10/15/24
3-Month
138.00 +16.18%
on 10/30/24
168.50 -4.85%
on 10/16/24
+10.37 (+6.92%)
since 08/15/24
52-Week
92.68 +72.99%
on 11/16/23
168.50 -4.85%
on 10/16/24
+65.86 (+69.72%)
since 11/15/23

Most Recent Stories

More News
Is Wall Street Bullish or Bearish on DaVita Stock?

While DaVita has outperformed the broader market over the past year, analysts on Wall Street are exercising caution regarding its future prospects.

XHS : 91.60 (-1.70%)
BCS : 13.21 (+1.93%)
$SPX : 5,870.62 (-1.32%)
DVA : 160.33 (+3.87%)
Why DaVita Stock Withered on Wednesday

The company's profitability is going in the wrong direction for many investors.

DVA : 160.33 (+3.87%)
DaVita (DVA) Q3 2024 Earnings Call Transcript

DVA earnings call for the period ending September 30, 2024.

DVA : 160.33 (+3.87%)
3 Top Healthcare Stocks to Buy for Growth and Dividends

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and...

UHS : 201.69 (+0.34%)
LLY : 746.20 (-4.93%)
GILD : 88.40 (-4.03%)
ISRG : 527.61 (-1.89%)
AMGN : 283.61 (-4.16%)
DVA : 160.33 (+3.87%)
Cencora Rallies 14.7% Year to Date: What's Driving the Stock?

Cencora, Inc. COR witnessed strong momentum in the year-to-date period. Shares of the company have rallied 14.7% compared with 2.8% growth of the industry. The S&P 500 Composite has risen 22.5% during...

BSX : 86.99 (-0.69%)
COR : 240.24 (-1.08%)
BAX : 31.96 (+0.82%)
DVA : 160.33 (+3.87%)
What to Expect From DaVita's Next Quarterly Earnings Report

DaVita is all set to release its third-quarter earnings this month, and analysts expect a single-digit profit dip.

XHS : 91.60 (-1.70%)
$SPX : 5,870.62 (-1.32%)
DVA : 160.33 (+3.87%)
Catalent Stock Flat Following the Sell Agreement With Ardena

Catalent CTLT recently announced that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ, to Ardena. Ardena is a Contract...

BSX : 86.99 (-0.69%)
CTLT : 59.10 (+0.32%)
BAX : 31.96 (+0.82%)
DVA : 160.33 (+3.87%)
BDX Stock Up on Robotics Solution Launch to Boost Single-Cell Research

Becton, Dickinson and Company BDX, popularly known as BD, announced the commercial launch of the first in a family of high-throughput, robotics-compatible reagent kits, BD OMICS-One XT Library Preparation...

BSX : 86.99 (-0.69%)
BDX : 225.15 (-0.89%)
BAX : 31.96 (+0.82%)
DVA : 160.33 (+3.87%)
SNN Stock May Gain Following the Co-Marketing Deal With JointVue

Smith & Nephew SNATS SNN recently announced the signing of a co-marketing agreement with JointVue for its patented OrthoSonic 3D Surgery Planning Technology, which is the only ultrasound device currently...

SNN : 24.89 (+1.01%)
BSX : 86.99 (-0.69%)
BAX : 31.96 (+0.82%)
DVA : 160.33 (+3.87%)
Here's Why You Should Add DaVita Stock to Your Portfolio Now

DaVita Inc. DVA has been gaining from its business model. The optimism, led by a solid second-quarter 2024 performance and the acquisition of dialysis centers, is expected to contribute further. However,...

COO : 99.63 (-0.23%)
DGX : 160.44 (+2.30%)
BAX : 31.96 (+0.82%)
DVA : 160.33 (+3.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals...

See More

Key Turning Points

3rd Resistance Point 167.86
2nd Resistance Point 164.14
1st Resistance Point 162.24
Last Price 160.33
1st Support Level 156.62
2nd Support Level 152.90
3rd Support Level 151.00

See More

52-Week High 168.50
Last Price 160.33
Fibonacci 61.8% 139.54
Fibonacci 50% 130.59
Fibonacci 38.2% 121.64
52-Week Low 92.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar